The BioInsights Podcast
The BioInsights Podcast: discussing the challenges of translating novel biologics from bench to clinic to market.
The BioInsights Podcast
Modernizing cell therapy manufacturing to reduce vein-to-vein times
•
David Backer, CEO Curate Biosciences
•
Season 2
•
Episode 8
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Charlotte Barker (Editor, BioInsights) speaks with Curate Biosciences’ CEO David Backer and CTO Tony Ward about the need for CAR-T cell therapy manufacturing to evolve, and how a new cell separation technique could boost efficiency.
How have you seen CAR-T cell therapies evolve over time?
What are the key challenges and priorities for CAR-T cell manufacture?
Why are the initial steps in apheresis or debulking important?
How does DCS microfluidics differ from other techniques?
How can DCS optimize the expansion of T cells?
Does cell separation impact subsequent genome editing steps?
Can manufacturing processes help ensure clinical efficacy?